Remote arm rehabilitation added to usual care after stroke in Brazil

Trial details

Who runs it

University of Sao Paulo

Trial code

NCT07646522

Record updated

16 June 2026

Original description

The purpose of this research study is to provide preliminary evidence of whether telerehabilitation targeting arm movement, when added to usual care, improves arm function and reduces global disability after stroke, compared to usual care alone in Brazil. Evaluate the safety and feasibility of telerehabilitation in the Brazilian context. Explore the clinical, neuroimaging, neurophysiological, and economic factors that influence telerehabilitation efficacy in functional recovery following stroke.Read full original descriptionShow less

Telerehabilitation and Biomarkers of Functional Recovery After Stroke in Brazil: TR-BR-1 Clinical Trial

The purpose of this research study is to provide preliminary evidence of whether telerehabilitation targeting arm movement, when added to usual care, improves arm function and reduces global disability after stroke, compared to usual care alone in Brazil. Evaluate the safety and feasibility of telerehabilitation in the Brazilian context. Explore the clinical, neuroimaging, neurophysiological, and economic factors that influence telerehabilitation efficacy in functional recovery following stroke.

Inclusion: Age 18-80 years at the time of randomization; The index stroke was radiologically verified, due to ischemia, and had time of onset 120±30 days prior to randomization; The stroke caused upper extremity deficits as defined by Action Research; Arm Test score 18-44 (out of 57) at Baseline Visit; Box \& Block Test score with affected arm is ≥1 block in 60 seconds at Baseline Visit; Able to successfully perform all 3 rehabilitation exercise test examples (simple commands) at Baseline Visit; Informed consent and behavioral contract signed by the subject (i.e., no surrogate consent).

Exclusion: Unable or unwilling to perform study procedures/therapy, or expectation of noncompliance with study procedures/therapy, or expectation that subject cannot participate in all study visits; Modified Rankin Scale score >2 prior to the index stroke; A new symptomatic stroke has occurred since the index stroke, or a separate stroke occurred within 30 days prior to the index stroke; Botulinum toxin to the paretic arm: received in the prior 3 months or expected by the 1-Month Visit; Concurrent enrollment in another therapy-based investigational study where the duration of the investigational therapy's activity is likely to occur during the subject's participation in the study; Expectation that participant will not have a single domicile address during the 6 weeks of therapy; A major, active, coexistent neurological, psychiatric, or medical disease that reduces the likelihood that a subject will be able to comply with all study procedures; A diagnosis (apart from the index stroke) that substantially affects paretic arm function; Significant cognitive impairment, defined as Montreal Cognitive Assessment [a lower score can be permitted at the discretion of the PI]; On isolation precautions, e.g., due to active COVID-19; Severe depression, defined as Geriatric Depression Scale Score >10/15 at Baseline Visit; Deficits in communication that interfere with reasonable study participation; Severe UE spasticity, defined as presence of contracture or modified Ashworth Scale score=4 in either biceps or pectoralis; Lacking visual acuity, with or without corrective lens, of 20/50 or better in at least one eye; Life expectancy < 9 months; Pregnancy; women of child-bearing potential must have a negative pregnancy test; Subject lacks sufficient Portuguese to comply with study procedures and TR instructions; Contraindication to MRI; Contraindication to TMS; Box and Block Test score of ≥30 blocks with the unaffected arm within 60 seconds at Baseline Visit; Spatial neglect interfering with reasonable participation in the study; Distance from the participant's home to the study site greater than 120 km [this can be waived at the discretion of the PI]; Availability of a 2 m² space for a table and chair setup.

ClinicalTrials.gov NCT07646522